ReviewNeurocritical care2010
Immunomodulatory therapies in neurologic critical care.
Review in Neurocritical care, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence.Frontiers in neurology · 2021Pooled it
- Methylprednisolone pulse therapy as an adjuvant treatment of Streptococcus pneumoniae meningitis complicated by cerebral infarction-a case report and review of the literature.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Pooled it
- Visual Function Improvement after Plasma Exchange Therapy for Acute Optic Neuritis in Neuromyelitis Optica Spectrum Disorders: Case Series and Review.Diagnostics (Basel, Switzerland) · 2024Review
- Randomized controlled double-blind trial of methylprednisolone versus placebo in patients with post-COVID-19 syndrome and cognitive deficits: study protocol of the post-corona-virus immune treatment (PoCoVIT) trial.Neurological research and practice · 2024Article
- Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review.Therapeutic advances in neurological disorders · 2023Review
- Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study.Therapeutic advances in neurological disorders · 2020Article
- A Longitudinally Extensive Spinal Cord Lesion Restricted to Gray Matter in an Adolescent Male.Frontiers in neurology · 2019Article
- CSF neopterin, a useful biomarker in children presenting with influenza associated encephalopathy?European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · 2019Article
- Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Current treatment options in neurology · 2017Review
- Acute influenza virus-associated encephalitis and encephalopathy in adults: a challenging diagnosis.JMM case reports · 2016Article
- Therapeutic benefits and side effects of Azathioprine and Aspirin in treatment of childhood primary arterial stroke.Annals of neurosciences · 2014Article
- Limbic encephalitis and related cortical syndromes.Current treatment options in neurology · 2013Article
- Treatment of acute disseminated encephalomyelitis.Current treatment options in neurology · 2012Article
- The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally.Clinical reviews in allergy & immunology · 2012Article
- Plasma exchange in severe attacks of neuromyelitis optica.Multiple sclerosis international · 2012Article
- Current and future treatment approaches for neuromyelitis optica.Therapeutic advances in neurological disorders · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
introductionNeurologic disorders with autoimmune dysregulation are commonly encountered in the critical care setting. Frequently encountered diseases include Guillain-Barré syndrome (GBS), myasthenia gravis, multiple sclerosis, acute demyelinating encephalomyelitis, and encephalitides. Immunomodulatory therapies, including high-dose corticosteroids, plasmapheresis, and intravenous immunoglobulins, are the cornerstone of the treatment of these diseases. Here we review the efficacy and side effects of immunomodulatory therapies commonly utilized in critically ill neurologic patients in the intensive care setting.
methodsSearch of Medline, Cochrane databases, and manual review of article bibliographies.
resultsThe efficacy of high-dose corticosteroids, plasmapheresis, and intravenous immunoglobulins have been studied extensively in GBS, myasthenia gravis, and demyelinating disorders such as multiple sclerosis and acute demyelinating encephalomyelitis. For these diseases, however, the duration of treatment, dosing regimens, and choices among different therapeutic modalities remain controversial. For many of the other diseases (e.g., encephalitis and status epilepticus of autoimmune etiology) discussed in this review, evidence is limited to small case series.
conclusionsThere is good evidence for the efficacy and tolerability of immunomodulatory therapies in GBS, myasthenia gravis, and acute central nervous system demyelination, though data to establish superiority of one therapeutic regimen over another remains lacking. For most other conditions, the data for immunomodulatory therapies are limited, and further research is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.